Singapore Cancer Pain Management Market Analysis Report [2022-30]

Singapore Cancer Pain Management Market Analysis

$ 3999

The Singapore Cancer Pain Management market is projected to grow from $7.82 Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022-30. The main factors driving the growth would be a robust healthcare system and increasing cancer cases. The market is segmented by drug type and by disease. Some of the major players include iX Biopharma (SGP), Medtronic, Hisamitsu Pharmaceutical, Mundipharma, Pfizer, Teva Pharmaceuticals, Abbott, and Sanofi.

ID: IN10SGHS002 CATEGORY: Healthcare Services GEOGRAPHY: Singapore AUTHOR: Neha Davda

Buy Now

Singapore Cancer Pain Management Market Executive Summary

The Singapore Cancer Pain Management market is projected to grow from $7.82 Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Singapore spent $2,633 on healthcare per capita in 2019, a decrease of 1.31% from the previous year. In comparison to many other developed countries, it spent a relatively modest 4.09% of its GDP on healthcare.

Most acute pain is caused by therapy or diagnostic procedures, but the majority of chronic pain is brought on by the illness. Chemotherapy and radiotherapy may result in uncomfortable problems that last long after the treatment is over. The presence of pain is mostly influenced by the location and stage of the tumor. Malignant cancer patients suffer pain at all times, and two-thirds of those who have progressed to cancer do so to the point where their sleep, emotions, social interactions, and daily activities are negatively impacted. The Asia-Pacific market for cancer pain management is one of the global markets with the fastest growth.

Market Dynamics

Market Growth Drivers

The healthcare system in Singapore is strong and well-developed, and it is set up to offer top-notch services. The availability of modern hospitals and clinics, along with skilled medical staff, is anticipated to boost the expansion of the cancer pain management market. Moreover, in Singapore, there were 80,753 cancer cases recorded between 2016 and 2020, with men and women reporting 49% and 51% of those cases, respectively. This robust healthcare system and increasing cancer cases will drive the growth of the pain management market in Singapore.

Market Restraints

The market for medications to treat cancer pain is expected to be constrained by the negative side effects of using these drugs, including drug dependence, drug tolerance, urine retention, sleep issues, and cognitive impairment. Furthermore, there is still a lack of awareness of the many pain management choices available in Singapore, which results in the underutilization of these medications.

Competitive Landscape

Key Players

iX Biopharma (SGP)
Medtronic
Hisamitsu Pharmaceutical
Mundipharma
Pfizer
Teva Pharmaceuticals
Abbott
Sanofi

Healthcare Policies and Regulatory Landscape

Singapore's healthcare laws and regulations are designed to give cancer patients access to pain relief that is secure, efficient, and reasonably priced. The Singapore Ministry of Health has established a number of policies to increase access to cancer pain management, including the promotion of pain management guidelines, the addition of potent pain medication to the list of essential medications, and financial assistance for patients with limited financial resources to purchase pain relievers.

The Health Sciences Authority (HSA) is in charge of overseeing the safety and effectiveness of medicines, medical equipment, and other healthcare items in Singapore, where the healthcare system is heavily controlled. The HSA is in charge of registering and importing new medications for use in Singapore. The HSA keeps a close eye on the efficacy and safety of drugs offered in Singapore to make sure that cancer patients have access to safe and effective pain management.

Reimbursement Scenario

In Singapore, patients have access to a variety of payment options, such as government grants and financial aid schemes. For instance, the MediShield Life program of the Ministry of Health offers financial assistance for medical care, including cancer pain management. MediFund additionally offers patients with financial challenges financial aid to cover their medical costs, including cancer pain treatment.

In Singapore, private health insurance is also readily accessible, and many of the policies include coverage for the costs of cancer pain management. Private health insurance may pay for treatments that aren't covered by government subsidies, giving patients access to a larger variety of pain management options.

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Cancer Pain Management Market Segmentation

By Drug Type (Revenue, USD Billion):

Non-steroidal anti-inflammatory medicines relieve pain at the site of injury by blocking the cyclooxygenase enzyme, which prevents prostaglandin formation. NSAIDs are a class of medications that includes medications with analgesic, antipyretic, and, at higher doses, anti-inflammatory properties.

Opioids
Morphine
- Fentanyl
- Others
Non-Opioids
Acetaminophen
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Nerve Blockers

By Disease Indication (Revenue, USD Billion):

Based on disease Indication the market is segmented into:

Lung Cancer
Colorectal cancer
Breast cancer
Prostate cancer
Blood cancer
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.